+122.1%
CME vs MRNA
+794.5%
-672.4%
-37.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -4.8% | +4.4% | -0.4% |
| 7D | -1.8% | -20.9% | +19.1% | -1.9% |
| 30D | +5.7% | -13.3% | +19.0% | +5.7% |
| 3M | +14.8% | +212.6% | -197.8% | +15.4% |
| 6M | +2.7% | +309.0% | -306.4% | +3.1% |
| YTD | +17.5% | +567.3% | -549.8% | +17.4% |
| 1Y | +15.4% | +689.7% | -674.3% | +15.1% |
| 3Y | +65.2% | +157.4% | -92.3% | +66.4% |
| 5Y | +69.2% | -21.7% | +90.9% | +71.8% |
| All | +122.1% | +794.5% | -672.4% | +123.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling